Abstract
ObjectivesOsteonecrosis of the jaw (ONJ) is one of the multiple side effects of bisphosphonate therapy. The incidence of ONJ among patients receiving intravenous (IV) bisphosphonates exceeds that recorded in patients treated with oral bisphosphonates. We report a case of spontaneous ONJ related to intravenous administration of bisphosphonates. Materials and methodsWe describe a case of spontaneous mandibular osteonecrosis in a female patient who underwent dental surgery before beginning therapy with bisphosphonates. ResultsThe patient's bone exposure was resolved, which illustrates that prompt, effective treatment can produce cures in patients with ONJ on IV bisphosphonate therapy and with other risk factors. ConclusionsPatients scheduled to undergo IV bisphosphonate therapy should be informed of its potential risks and treated in accordance with a precise therapeutic procedure that includes a dental evaluation before treatment. This approach ensures rapid resolution of possible treatment-related complications via consultation and collaboration of various medical specialists.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
